-
1
-
-
0018716636
-
Risk factors for doxorubicin-induced congestive heart failure
-
Von Hoff D, Layard M, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
-
(1979)
Ann. Intern. Med.
, vol.91
, pp. 710-717
-
-
Von Hoff, D.1
Layard, M.2
Basa, P.3
-
3
-
-
0032563825
-
Current concepts: Doxorubicin-induced cardiomyopathy
-
Singal P, Iliskovic N. Current concepts: doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905.
-
(1998)
N. Engl. J. Med.
, vol.339
, pp. 900-905
-
-
Singal, P.1
Iliskovic, N.2
-
4
-
-
0031852560
-
Anthracycline cardiotoxicity, no longer an issue?
-
Green M. Anthracycline cardiotoxicity, no longer an issue? Ann Oncol 1998; 9: 691-693.
-
(1998)
Ann. Oncol.
, vol.9
, pp. 691-693
-
-
Green, M.1
-
5
-
-
0028989408
-
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
-
Lipschultz S, Lipsitz S, Mone S et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. New Engl J Med 1995; 332: 1738-1743.
-
(1995)
New Engl. J. Med.
, vol.332
, pp. 1738-1743
-
-
Lipschultz, S.1
Lipsitz, S.2
Mone, S.3
-
6
-
-
0035155497
-
Anthracycline-induced clinical heart failure in a cohort of 607 children: Long term follow-up study
-
Kremer L, Van Dalen E, Offringa M et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long term follow-up study. J Clin Oncol 2001; 19: 191-196.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 191-196
-
-
Kremer, L.1
Van Dalen, E.2
Offringa, M.3
-
7
-
-
0034643399
-
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy
-
Felker M, Thompson R, Hare J et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-1084.
-
(2000)
N. Engl. J. Med.
, vol.342
, pp. 1077-1084
-
-
Felker, M.1
Thompson, R.2
Hare, J.3
-
8
-
-
0030904457
-
Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience
-
Krisher J, Epstein S, Cuthbertson D et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997; 15: 1544-1552.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 1544-1552
-
-
Krisher, J.1
Epstein, S.2
Cuthbertson, D.3
-
9
-
-
0026031848
-
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
-
Lipschultz S, Colan S, Gelber R et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815.
-
(1991)
N. Engl. J. Med.
, vol.324
, pp. 808-815
-
-
Lipschultz, S.1
Colan, S.2
Gelber, R.3
-
10
-
-
0025850827
-
Cardiac toxicity 4 to 20 years after completing anthracycline therapy
-
Steinherz L, Steinherz P, Tan C et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.
-
(1991)
JAMA
, vol.266
, pp. 1672-1677
-
-
Steinherz, L.1
Steinherz, P.2
Tan, C.3
-
11
-
-
0031017043
-
Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity
-
Sorensen K, Levitt G, Bull C et al. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 1997; 15: 61-68.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 61-68
-
-
Sorensen, K.1
Levitt, G.2
Bull, C.3
-
12
-
-
0030904096
-
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
-
Swain S, Whaley F, Gerber M et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-1332.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 1318-1332
-
-
Swain, S.1
Whaley, F.2
Gerber, M.3
-
13
-
-
0035282073
-
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer
-
Batist G, Ramakrishnan G, Sekhar Rao C et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 1444-1454
-
-
Batist, G.1
Ramakrishnan, G.2
Sekhar Rao, C.3
-
14
-
-
0035125066
-
Survival in patients with intermediate or high-grade non-Hodgkin's lymphoma: Meta-analysis of randomized studies comparing third generation regimens with CHOP
-
Messori A, Vaiani M, Trippoli S. Survival in patients with intermediate or high-grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84: 303-307.
-
(2001)
Br. J. Cancer
, vol.84
, pp. 303-307
-
-
Messori, A.1
Vaiani, M.2
Trippoli, S.3
-
15
-
-
0031801499
-
Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas
-
Haddy T, Adde M, McCalla J et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol 1998; 16: 2070-2079.
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 2070-2079
-
-
Haddy, T.1
Adde, M.2
McCalla, J.3
-
16
-
-
0018757883
-
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography
-
Alexander J, Dainiak N, Berger H et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300: 278-283.
-
(1979)
N. Engl. J. Med.
, vol.300
, pp. 278-283
-
-
Alexander, J.1
Dainiak, N.2
Berger, H.3
-
17
-
-
0023634395
-
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography
-
Schwartz R, McKenzie W, Alexander J et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109-1118.
-
(1987)
Am. J. Med.
, vol.82
, pp. 1109-1118
-
-
Schwartz, R.1
McKenzie, W.2
Alexander, J.3
-
18
-
-
0020038042
-
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
-
Legha S, Benjamin R, Mackay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-139.
-
(1982)
Ann. Intern. Med.
, vol.96
, pp. 133-139
-
-
Legha, S.1
Benjamin, R.2
Mackay, B.3
-
19
-
-
0032921354
-
Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: Autonomic versus echocardiographic variables
-
Tjeerdsma G, Meinardi M, Van der Graf W et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81: 419-423.
-
(1999)
Heart
, vol.81
, pp. 419-423
-
-
Tjeerdsma, G.1
Meinardi, M.2
Van der Graf, W.3
-
20
-
-
0032983504
-
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin
-
Herman E, Zhang J, Lipschultz E et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17: 2237-2243.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 2237-2243
-
-
Herman, E.1
Zhang, J.2
Lipschultz, E.3
-
21
-
-
0030882421
-
Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
-
McDonagh T, Morrison C, Lawrence A et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-833.
-
(1997)
Lancet
, vol.350
, pp. 829-833
-
-
McDonagh, T.1
Morrison, C.2
Lawrence, A.3
-
22
-
-
0035845307
-
Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: A population based study
-
Davies M, Hobbs F, Davis R et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: a population based study. Lancet 2001; 358: 439-444.
-
(2001)
Lancet
, vol.358
, pp. 439-444
-
-
Davies, M.1
Hobbs, F.2
Davis, R.3
-
23
-
-
0032872127
-
American, Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
-
Hensley M, Schuchter L, Lindley C et al. American, Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-3355.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 3333-3355
-
-
Hensley, M.1
Schuchter, L.2
Lindley, C.3
-
24
-
-
0004815869
-
CHOP is the standard regimen in patients ≥70 years of age with intermediate grade or high grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
-
Tirelli U, Errante D, Van Glabbeke M et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate grade or high grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 27-34.
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 27-34
-
-
Tirelli, U.1
Errante, D.2
Van Glabbeke, M.3
-
25
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Brière, J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 2002; 346: 235-242.
-
(2002)
New Engl. J. Med.
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Brière, J.3
-
26
-
-
0032100459
-
A randomized comparison of the efficacity and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma
-
Nair R, Ramakrishnan G, Nair N et al. A randomized comparison of the efficacity and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma. Cancer 1998; 82: 2282-2288.
-
(1998)
Cancer
, vol.82
, pp. 2282-2288
-
-
Nair, R.1
Ramakrishnan, G.2
Nair, N.3
-
27
-
-
0031698016
-
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy
-
Phillips K, Tannock I. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998; 16: 3179-3190.
-
(1998)
J. Clin. Oncol.
, vol.16
, pp. 3179-3190
-
-
Phillips, K.1
Tannock, I.2
-
28
-
-
0032951328
-
International consensus conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: Report of the jury
-
Shipp M, Abeloff M, Antman K et al. International consensus conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury. J Clin Oncol 1999; 17: 423-429.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 423-429
-
-
Shipp, M.1
Abeloff, M.2
Antman, K.3
-
29
-
-
0033890745
-
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH-87 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study
-
Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH-87 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
-
(2000)
J. Clin. Oncol.
, vol.18
, pp. 3025-3030
-
-
Haioun, C.1
Lepage, E.2
Gisselbrecht, C.3
-
30
-
-
17744376759
-
Severe toxicity in hematological stem cell transplantation: Predictive value of reduced left ventricular ejection fraction
-
Fujimaki K, Maruta A, Yoshida M et al. Severe toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001; 27: 307-310.
-
(2001)
Bone Marrow Transplant.
, vol.27
, pp. 307-310
-
-
Fujimaki, K.1
Maruta, A.2
Yoshida, M.3
|